cleanascitealzheimerdisease
Moreover, the patent describes the search for serological biomarkers of Alzheimer's disease (AD) by studying redox-reactive autoantibodies (R-RAA) present in serum which unmask antigen recognition sites upon oxidative exposure. The autoantibodies are detected in blood with an oxidizing agent and using a screening assay to detect antibodies that bind a self antigen. Hemin is the oxidizing agent used for R-RAA aPE ELISA. Inventor John Mcintyre developed technology to ‘unmask’ autoantibodies in serum samples in vitro and matched AD specific epitopes to reactive autoantibodies. The increase in R-RAA aPE in MCI serum samples and changes in hippocampal choline acetyltransferase (ChAT) in end-stage AD or MCI are being exploited as potential biomarkers. Using ELISA to quantitatively measure concentration of unmasked antibodies in serum samples in vitro by the presence of their recognition epitopes, the increase in R-RAA over their base line values and comparison to the increased ELISA reactivity in AD and/or normal individuals is determined. Comparisons between the AD and normal populations revealed highly significant differences in R-RAA antiphosphatidylethanolamine (aPE).
Characteristics of Cleanascite™
A high binding capacity for lipids with minimal cross-reactivity with proteins
Effectively replaces chlorinated/
Helps purify antibodies, recombinant proteins, nucleic acids, proteoglycans
Ideal for clarifying ascites, serum, cell & tissue culture, bile and organ homogenates
Very low protein binding
Does not bind to DNA, RNA, enzymes and proteins
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™
CONTACT:
Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
732-274-2866
sales@biotechsupportgroup.com
For more information on Cleanascite™
http://www.biotechsupportgroup.com/
Cleanascite™
United States Patent Application 20120107841:
Lijowski M, Caruthers S, Hu G. High-Resolution SPECT-CT/MR Molecular Imaging of Angiogenesis in the Vx2 Model Investigative Radiology.2009;
Turner JD, Langley RS, Johnston KL. Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis The Journal of Biological Chemistry.2009;
Torrelles JB, DesJardin LE, MacNeil J. et al Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipoarabinomannan and lipomannan content and increases the rate of bacterial-induced human macrophage cell death Glycobiology.2009;
Cho N, Chueh PJ, Kim C et al Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunology, Immunotherapy. 2002;51(3):121-
Shapiro S, Beenhouwer DO, Feldmesser M et al. Immunoglobulin G Monoclonal Antibodies to Cryptococcus neoformans Protect Mice Deficient in Complement Component C3 Infect. Infection and immunity.2002;
Castro AR, Morrill We, Pope V. Lipid Removal from Human Serum Samples Clinical and diagnostic laboratory immunology.2000;
Nussbaum G, Cleare W, Casadevall A et al Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody Efficacy The Journal of experimental medicine.1997;
For more information about Cleanascite™
Suggested References
Samgard, K., et al. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. International journal of geriatric psychiatry.2010;
Hu, W. T., et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathologica. 2010; 119(S6):669-
Petersen, R C., et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology.2010;
Cedazo-Minguez, A., and Winblad, B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental gerontology.2010;
Cedazo-Minguez, A., and Winblad, B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental gerontology.2010;
McIntyre, J A & Faulk W P. Redox-reactive autoantibodies:
McIntyre, J A, Wagenknecht, D R, and Ramsey, C J. Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls. Autoimmunity.2009;
Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine.2007;
McIntyre, J A, Wagenknecht, D R, & Faulk, W P. Redox-reactive autoantibodies:
McIntyre, J A, Wagenknecht, D R, & Faulk, W P. Autoantibodies unmasked by redox reactions. Journal of autoimmunity. 2005;24:311-
McIntyre, J A. The appearance and disappearance of antiphospholipid antibodies subsequent to oxidation-reduction reactions. Thrombosis research.2004;
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., and Mufson, E. J.Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of neurology.2002;
Photo:
http://www.prlog.org/
